Cue Biopharma, Inc. (CUE): Capital Expenditures
$177.0K
Year ended 2025-12-31
$121.0K
Trailing 12 months to 2026-06-30
+1.2%
3-year compound annual growth
-21.5%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $177.0K | +168.2% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $66.0K | n/a | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $0 | -100.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $171.0K | -81.3% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $913.0K | +53.4% | 2023-03-21, From 2021-01-01 |
| 2020-12-31 | $595.3K | n/m | 2022-03-16, From 2020-01-01 |
| 2019-12-31 | $46.4K | -97.5% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $1.85M | +80.0% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $1.03M | n/a | 2019-03-14, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $177.0K | +168.2% |
| Celularity Inc (CELU) | 2024-12-31 | $161.0K | -84.6% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $1.04M | -67.0% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $50.0K | -94.5% |
| Verastem, Inc. (VSTM) | 2024-12-31 | $28.0K | n/a |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $567.0K | -89.1% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | $2.35M | -16.9% |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗